Chart of Day: Relay Therapeutics (RLAY) – 5/12

Keep eye on Relay Therapeutics (SYM: RLAY).

Analysts at Barclays just upgraded the stock to an overweight rating, with a price target of $15 a share. As noted by CNBC, the firm noted “there is a potential $4 billion market opportunity ‘for a mutant selective PI3Kalpha inhibitor’ tied to treatments for HR+/HER2- breast cancer, or roughly 35% of the $12 billion in total sales in 2024 expected for another class of drugs; CDK4/6 inhibitors (palbociclib, ribociclib, abemaciclib) approved in HR+/HER2-.”


“We believe the 2H update will help show the superior efficacy/safety profile for Relay’s PI3Kalpha (RLY-2608) over existing PI3Kalpha inhibitors like alpelisib and inavolisib.”

In addition, as noted by Sanjiv Patel, M.D., President and Chief Executive Officer of Relay Therapeutics, the company does expect to share more data in the second half of the year.

deal of the month

best growth stocks


Bundle package – lifetime subscriptions for all products


Recent posts


Connect with Us

Get FREE Daily Stock Tips

Join and receive market insider stock picks, trade alerts and unique investing insights
This field is for validation purposes and should be left unchanged.
By clicking the "Subscribe" button you are accepting our Terms of Use and Privacy Policy.

Join Waitlist

We’re sorry, but due to the popularity of our services, we have reached our max number of subscribers and are not currently accepting more. If spots become available, we will be sure to contact you. Please join the waitlist below.
Thank You!

"*" indicates required fields

This field is for validation purposes and should be left unchanged.